Tag: Cardialen

Cardialen Announces Positive Results from Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation

MultiPulse Therapy™ (MPT™) achieved 71% termination of acute, induced atrial fibrillation (AF) episodes at energy levels deemed to be tolerable for patients1,2 MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has published a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology titled Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation. The study […]

Cardialen Awarded $2.8 Million Federal Grant to Advance Therapy Designed to Treat Dangerous Heart Rhythms

National Institutes of Health grant will support Cardialen’s development of its implantable, low-energy therapy designed to treat atrial fibrillation, a cardiac arrhythmia associated with debilitating shortness of breath, fatigue, pain, and an increased risk of stroke. MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has been awarded a $2.8 million National Institutes of Health (NIH) […]

Cardialen Closes $17 Million Series B Financing for Heart Rhythm Therapy

MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., a medical device company developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm, announced today the closing of a $17 million Series B investment led by RiverVest Venture Partners, along with Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The financing will […]